Adenoviral Vectors for Gene Therapy, Third Edition, provides detailed, comprehensive coverage of gene delivery vehicles based on the adenovirus that is emerging as an important tool in gene therapy. These exciting new therapeutic agents have great potential for the treatment of disease, as platforms for gene therapy and gene editing, as well as for oncology approaches, making them class leading agents in the gene-advanced therapies arena. The fully updated and expanded third edition covers the basic biology of adenoviruses and highlights the potential use of adenoviral vectors for the treatment of disease, including their construction, propagation, and purification, cutting-edge vectorology, and the use of adenoviral vectors in preclinical animal models. The book also considers the regulatory issues surrounding human clinical gene therapy trials. New chapters include adenoviral vaccines for veterinary applications, adenoviruses for gene editing, nonhuman primate adenoviruses, COVID-19 vaccines, vaccine applications, and oncolytic adenoviruses for antitumor immunization. This broad scope of information provides a solid overview of the field, allowing the reader to gain a complete understanding of the development and use of adenoviral vectors.
Les mer
1. Structural Biology of Adenovirus 2. Biology of Adenovirus Cell Entry: Receptors, Pathways, Mechanisms 3. Adenovirus Replication 4. Adenoviral Vector Construction I: Mammalian Systems 5. Adenoviral Vector Construction II: Bacterial Systems 6. Adenoviral Vector Packing Cell Lines 7. Purification of Adenovirus 8. Innate Immune Response to Adenovirus 9. Antibodies to Adenovirus 10. Methods to Mitigate Immune Response 11. Xenogenic Adenoviral Vectors as Vaccines 12. Adenoviral Vector Targeting 13. Helper-Dependent Adenovirus 14. Hybrid Adenoviral Vectors 15. Canine Adenovirus 16. Oncolytic Adenovirus 17. Imaging Analysis 18. Adenoviral Vaccines - Cancer 19. Adenoviral Vaccines - Infectious Disease 20. Adenoviral Vaccines - COVID 19 21. Adenoviral Vectored Veterinary Vaccines 22. Utility of Adenoviral Vectors in Animal Models - CV Disease 23. Utility of Adenoviral Vectors in Animal Models - Pulmonary Disease 24. Utility of Adenoviral Vectors in Animal Models - Genetic Disease 25. Adenoviral Vectors for Gene Editing 26. Manufacturing and Upscaling 27. Regulation of Adenoviral Vector-Based Therapies: An FDA Perspective
Les mer
Comprehensive and fully updated and expanded third edition which provides the latest coverage of the adenoviral vector as a gene delivery vehicle, an important emerging tool in gene therapy
Provides complete coverage of the basic biology of adenoviruses, as well as their construction, propagation, and purification of adenoviral vectors Introduces common strategies for the development of adenoviral vectors, along with cutting-edge methods for their improvement Demonstrates noninvasive imaging of adenovirus-mediated gene transfer Discusses the utility of adenoviral vectors in animal disease models Considers Food and Drug Administration regulations for human clinical trials
Les mer

Produktdetaljer

ISBN
9780323898218
Publisert
2025-06-12
Utgave
3. utgave
Utgiver
Elsevier Science & Technology; Academic Press Inc
Vekt
450 gr
Høyde
235 mm
Bredde
191 mm
Aldersnivå
P, 06
Språk
Product language
Engelsk
Format
Product format
Innbundet
Antall sider
906

Om bidragsyterne

David T. Curiel, M.D., Ph.D. is the Director of the Cancer Biology Division of the Department of Radiation Oncology at Washington University School of Medicine. Dr. Curiel graduated medical school at Emory University in 1982, where he also completed his internship and residency in Internal Medicine. Dr. Curiel’s scientific training includes tenureship at the National Institutes of Health in Bethesda, Maryland at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI) from 1985-1989, and a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch from 1989-1990. He received his Ph.D. from University of Groningen in The Netherlands in 2002. Dr. Curiel has been at Washington University School of Medicine since 2011. In addition to his role as Director of the Cancer Biology Division, he is Director of the Biologic Therapeutics Center.